Drug profile

The FDA adverse-event record for Leptospira Canicola, C-51, Kb; Leptospira Grippotyphosa, Mal 1540, Kb; Leptospir

15 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Leptospira Canicola, C-51, Kb; Leptospira Grippotyphosa, Mal 1540, Kb; Leptospir. See the species affected, top reactions, and outcomes below.

15
adverse-event reports
6.7%
death-coded share
Dog
most-reported species
4
Other abnormal test result NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
1
Deaths Reported
6.7%
Death Rate

Active Ingredients

Leptospira Canicola, C-51, Kb; Leptospira Grippotyphosa, Mal 1540, Kb; Leptospir

Administration Routes

Subcutaneous

Species Affected

Dog 15

Most Affected Breeds

Boxer (German Boxer) 3
Crossbred Canine/dog 2
Poodle - Standard 2
Poodle - Miniature 1
Retriever - Labrador 1
Dachshund - Standard Long-haired 1
Shih Tzu 1
Pug 1
Schnauzer - Miniature 1
Terrier - Bull - American Pit 1

Most Reported Reactions

Other abnormal test result NOS 4
Emesis 3
Anaphylaxis 3
Urticaria 3
Lethargy (see also Central nervous system depression in 'Neurological') 3
Circulatory collapse (see also 'Neurological' and 'Systemic disorders') 2
Lameness 2
Anaphylactoid reaction 2
Injection site swelling 2
Vomiting 2
Fever 2
Seizure NOS 2

Outcome Breakdown

Ongoing
10 (66.7%)
Recovered/Normal
4 (26.7%)
Euthanized
1 (6.7%)

Leptospira Canicola, C-51, Kb; Leptospira Grippotyphosa, Mal 1540, Kb; Leptospir Adverse Event Insights

15 reports name Leptospira Canicola, C-51, Kb; Leptospira Grippotyphosa, Mal 1540, Kb; Leptospir; 1 recorded a death outcome (6.7% of reported events, not a population-level mortality rate). Active ingredient: Leptospira Canicola, C-51, Kb; Leptospira Grippotyphosa, Mal 1540, Kb; Leptospir. Administration route: Subcutaneous.

By species: Dog (15 reports). By breed: Boxer (German Boxer) (3), Crossbred Canine/dog (2), Poodle - Standard (2).

Leading clinical signs: Other abnormal test result NOS (4), Emesis (3), Anaphylaxis (3), Urticaria (3). Outcome, 15 coded reports: Ongoing leads at 66.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.